Health Care & Life Sciences » Biotechnology | Oncimmune Holdings PLC

Oncimmune Holdings PLC | Cash Flow

Fiscal year is June-May. All values GBP Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
1,412.00
2,013.00
8,442.00
5,023.00
6,342
Depreciation, Depletion & Amortization
41.00
41.00
78.00
91.00
180
Other Funds
966.00
547.00
5,369.00
296.00
115
Funds from Operations
2,337.00
1,425.00
2,995.00
4,636.00
6,047
Changes in Working Capital
191.00
80.00
179.00
357.00
54
Net Operating Cash Flow
2,146.00
1,505.00
3,174.00
4,279.00
6,101
Capital Expenditures
43.00
52.00
172.00
422.00
Sale of Fixed Assets & Businesses
947.00
-
-
-
Net Investing Cash Flow
904.00
52.00
172.00
422.00
Issuance/Reduction of Debt, Net
1,796.00
1,246.00
827.00
388.00
Net Financing Cash Flow
1,800.00
1,246.00
12,275.00
388.00
Net Change in Cash
434.00
224.00
8,853.00
5,122.00
Free Cash Flow
2,189.00
1,522.00
3,238.00
4,286.00
Change in Capital Stock
4.00
-
11,448.00
-
Exchange Rate Effect
124.00
87.00
76.00
33.00

About Oncimmune Holdings

View Profile
Address
Clinical Sciences Building
Nottinghamshire Nottingham NG5 1PB
United Kingdom
Employees -
Website http://www.oncimmune.com
Updated 07/08/2019
Oncimmune Holdings Plc is an early cancer detection company that engages in the development and commercialization of its proprietary EarlyCDT platform technology. It has pioneer the development of tests based on the presence in the blood of autoantibody against specific tumor associated antigens that have the potential to detect cancer up to four years earlier than other methods of cancer detection, such as a chest X-ray, Spiral Computed Tomography or emerging technologies that do not benefit from the amplification of signal that occurs with the immune system, and can be applied to a very wide range of solid tumor types. The company was founded on October 9, 2015 and is headquartered in Nottinghamshire, the United Kingdom.